



Seres Therapeutics Announces Closing of Initial Public Offering

July 1, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 1, 2015-- Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced the closing of its initial public offering of 8,545,138 shares of its common stock at an initial public offering price of \$18.00 per share, which includes the exercise in full by the underwriters of their option to purchase 1,114,583 additional shares of common stock. The shares began trading on the NASDAQ Global Select Market under the ticker symbol "MCRB" on June 26, 2015. All of the shares of common stock in the offering were offered by the company. The net proceeds to Seres Therapeutics from the sale of shares in the offering are estimated to be approximately \$139.8 million, after deducting the underwriting discounts and estimated offering expenses.

Goldman, Sachs & Co. and BofA Merrill Lynch acted as joint book-running managers for the offering, and Leerink Partners and Canaccord Genuity Inc. acted as lead managers for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 25, 2015. This offering was made only by means of a prospectus. Copies of the final prospectus relating to this offering may be obtained by contacting Goldman, Sachs & Co. by mail at 200 West Street, New York, New York 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com or BofA Merrill Lynch, by mail at 222 Broadway, New York, New York 10038, Attention: Prospectus Department, or by email at dg.prospectus_requests@baml.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20150701006559/en/>

Source: Seres Therapeutics, Inc.

Investor Relations

Stern Investor Relations Inc.
Beth DelGiacco, 212-362-1200
Beth@sternir.com